Creative Biomart Blog

Tue, 2023/04/25

Special Protein FAM193A with Novel Anti-Tumor Activity

Scientists from institutions such as the Anschutz School of Medicine at the University of Colorado have discovered and characterized a specific protein that is primarily involved in the specific mechanisms that inhibit the progression of different types of tumors. Understanding how cancer occurs is crucial for designing effective personalized cancer therapies. For many years, researchers have known that cancer begins with mutations in certain types of genes, one of which is called “tumor suppressors”, Tumor suppressor genes block uncontrolled cell proliferation in malignant cells and initia

Thu, 2023/03/30

M6A Targeted Modification Can Improve Immune checkpoint Therapy

The immune system acts as a guardian of the host by initiating an immune response to harmful pathogens and tumor cells. However, overreaction is the cause of chronic or excessive inflammation and autoimmune diseases. Immune checkpoints play a key role in regulating the size of immune responses, thereby maintaining immune homeostasis and self-tolerance. However, tumor cells can also use immune checkpoints to evade immune surveillance, suppress anti-tumor immune responses, and ultimately lead to tumor genesis and tumor progression. Recently, researchers from Qilu Medical College published an

Thu, 2023/03/30

The Role of the Third Intracellular Ring of GPCR in GPCR Signal Conduction Mechanism

In a new study, American researchers have discovered the role of the third intracellular loop of GPCR in the GPCR signal transduction mechanism, indicating the possibility of adopting more targeted drug discovery methods and developing new drugs. More than one-third of the drugs approved by the United States Food and Drug Administration (FDA) function by targeting G protein-coupled receptors (GPCRs). The human body has over 800 types of GPCRs, which provide cells with information about the external environment to calibrate the body's response. Drugs that block or activate GPCR are used to t

Thu, 2023/03/30

The Base Editor Is Expected to Be Used for the Treatment of CD3Δ Severe Combined Immunodeficiency

In a new study, researchers from research institutions such as the University of California, Los Angeles, discovered that advanced genome editing technology may be able to be used for a rare and fatal genetic disease, D3 delta severe combined immunodeficiency, CD3δ SCID, for a one-time treatment. The relevant research results were published online in Cell, with the title “Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing”. CD3δ SCID is caused by a mutation in the CD3D gene, which blocks the production of CD3δ proteins that are required

Thu, 2023/03/30

Understand the mechanism of action of CFTR to better treat cystic fibrosis

In a new study, researchers from St. Jude's Children's Research Hospital and Rockefeller University in the United States combined their expertise to gain a better understanding of a protein called cystic fibrosis transmembrane conductance regulator (CFTR). Mutations in CFTR cause cystic fibrosis, a fatal disease that cannot be cured. The relevant research results were published online in the journal Nature, with the title “CFTR function, physiology and pharmacology at single molecule resolution”. Currently, treatment with a drug called a potentiator can enhance the CFTR function of some pat

Thu, 2023/03/02

Interferon-gamma (IFNG) drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer

Immunotherapy - drug therapy that stimulates the immune system to attack tumors - has a good effect on some types of cancer, but its effect on lung cancer is mixed. A new study helps to clarify why the immune system responds so weakly to lung cancer, even after treatment with immunotherapy drugs. In this study on mice, researchers from the Massachusetts Institute of Technology found that bacteria found naturally in the lungs can help build an environment that inhibits the activation of T cells in lymph nodes near the lungs. They did not find that immunosuppressive environment in the lymph n

Thu, 2023/03/02

ROR2 may be a potential biomarker of prostate cancer

Prostate cancer (PCa) is the main cause of cancer-related deaths in men. Androgen deprivation therapy (ADT) is still the standard systemic treatment, but patients always progress to metastatic castrated tolerant prostate cancer (mCRP C). Most of these tumors will react to the further treatment of androgen signaling inhibitors (ASIs), but inevitably will produce drug resistance. Changes in androgen receptor (AR) and interaction pathway contribute to the sustained activity of AR and tumor growth in many cases, while other tumors are independent of AR, and some of them have neuroendocrine char

Thu, 2023/03/02

AMPK activation is a promising strategy to reduce the risk of melanoma

Skin cancer is the most common cancer in the United States, with about 5 million cases every year. Melanoma is less common than other types of skin cancer, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), but it causes most of the death of skin cancer. The risk of melanoma is related to environmental factors, such as ultraviolet radiation (UVR) and genetic background. It is noteworthy that the melanocortin-1 receptor (MC1R) is the central regulator of pigmentation and is related to the occurrence of melanoma. MC1R is a G-protein-coupled receptor, which plays a key rol